Strategic partnerships Astex has active and high-profile oncology collaboration deals with Genentech, Roche, Janssen, AstraZeneca, MSD, and Taiho, indicating strong partner receptivity to external programs and potential co-development or license opportunities in oncology and KRAS inhibitor programs.

Early stage to clinic With a proprietary Fragment-Based Drug Discovery platform that has yielded multiple drug candidates progressing in clinical development, there are opportunities to license or co-develop early-stage assets or leverage Astex’s FBDD expertise to advance external programs.

Breast cancer focus Recent announcements around breast cancer therapy programs and a Genentech collaboration suggest a growing strategic emphasis in breast cancer; sales teams should target biotech and pharma partners seeking innovative breast cancer solutions and IP leverage.

KRAS collaboration Ongoing partnerships around KRAS inhibitors with Taiho and MSD indicate a strong track record in challenging targets, presenting doors for new collaborations in KRAS-driven indications and potential expansion of program scope with interested pharma buyers.

Emerging capabilities Astex maintains cloud-based infrastructure and modern tech stack (AWS, GitHub, Terraform, Docker) with a growing Cambridge presence; cross-sell opportunities exist for CROs, platform-enabled discovery services, and integrated biotech collaborations seeking scalable drug discovery capabilities.